The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow
Open accessAbstract
Oncolytic viruses (OVs) are selected or designed to eliminate malignancies by direct infection and lysis of cancer cells. In contrast to this concept of direct tumor lysis by viral infection, we observed that a significant portion of the in vivo tumor killing activity of two OVs, vesicular stomatitis virus (VSV) and vaccinia virus is caused by indirect killing of uninfected tumor cells. Shortly after administering the oncolytic virus we observed limited virus infection, coincident with a loss of blood flow to the interior of the tumor that correlated with induction of apoptosis in tumor cells. Transcript profiling of tumors showed that virus infection resulted in a dramatic transcriptional activation of pro-inflammatory genes including the neutrophil chemoattractants CXCL1 and CXCL5. Immunohistochemical examination of infected tumors revealed infiltration by neutrophils correlating with chemokine induction. Depletion of neutrophils in animals prior to VSV administration eliminated uninfected tumor cell apoptosis and permitted more extensive replication and spreading of the virus throughout the tumor. Taken all together, these results indicate that targeted recruitment of neutrophils to infected tumor beds enhances the killing of malignant cells. We propose that activation of inflammatory cells can be used for enhancing the effectiveness of oncolytic virus therapeutics, and that this approach should influence the planning of therapeutic doses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neutrophils and immunity: challenges and opportunities
Nathan, C. (2006) · Nature reviews. Immunology · doi:10.1038/nri1785 · Cited by 2,971
The two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Leukocyte-endothelial interactions
Harlan, J. (1985) · Blood · doi:10.1182/blood.v65.3.513.513 · Cited by 872
Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 842
Self-citationOxidants from phagocytes: agents of defense and destruction
Babior, B. (1984) · Blood · doi:10.1182/blood.v64.5.959.959 · Cited by 807
Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins.
Henson, P. M., & Johnston, R. B. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112869 · Cited by 693
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4
Tepper, R. I., Coffman, R. L., & Leder, P. (1992) · Science · doi:10.1126/science.1636093 · Cited by 541
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Self-citationVascular ischaemia and reperfusion injury
Eltzschig, H. K., & Collard, C. D. (2004) · British Medical Bulletin · doi:10.1093/bmb/ldh025 · Cited by 456
Blood clearance rates of adenovirus type 5 in mice
Alemany, R., Suzuki, K., & Curiel, D. T. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2605 · Cited by 413
McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., & Bartlett, D. L. (2001) · PubMed · Cited by 366
Self-citationCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Unique Structural Features That Influence Neutrophil Emigration Into the Lung
Burns, A. R., Smith, C. W., & Walker, D. C. (2003) · Physiological Reviews · doi:10.1152/physrev.00023.2002 · Cited by 297
Shayakhmetov, D. M., Li, Z.-Y., Ni, S., & Lieber, A. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5368-5381.2004 · Cited by 210
The Role of CC Chemokine Receptor 2 in Alveolar Monocyte and Neutrophil Immigration in Intact Mice
Maus, U., von Grote, K., Kuziel, W. A., Mack, M., Miller, E. J., Cihak, J., Stangassinger, M., Maus, R., Schlöndorff, D., Seeger, W., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2112012 · Cited by 195
Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity
Power, A. T., Wang, J., Falls, T. J., Paterson, J. M., Parato, K. A., Lichty, B. D., Stojdl, D. F., Forsyth, P. A. J., Atkins, H., & Bell, J. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300039 · Cited by 191
Self-citationAdenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery
Lyons, M. J., Onion, D., Green, N. K., Aslan, K., Rajaratnam, R., Bazán‐Peregrino, M., PHIPPS, S. L., Hale, S. J. M., Mautner, V., Seymour, L. W., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.003 · Cited by 156
Ikeda, K., Wakimoto, H., Ichikawa, T., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4765-4775.2000 · Cited by 154
Chen, Y., Yu, D., Charlton, D., & Henderson, D. (2000) · Human Gene Therapy · doi:10.1089/10430340050083289 · Cited by 143
Reid, T. R., Freeman, S., Post, L. E., McCormick, F. P., & Sze, D. Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700819 · Cited by 115
Getting oncolytic virus therapies off the ground
Bell, J. C., Lichty, B. D., & Stojdl, D. F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00170-3 · Cited by 109
Self-citationJiang, H., Wang, Z., Serra, D. M., Frank, M. M., & Amalfitano, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.015 · Cited by 84
Striking out at disseminated metastases: the systemic delivery of oncolytic viruses.
Fisher, K. (2006) · PubMed · Cited by 59
Korthuis, R. J., & Gute, D. C. (2008) · International Journal of Microcirculation · doi:10.1159/000179261 · Cited by 57
Oncolytic viruses as novel anticancer agents: turning one scourge against another
Chiocca, E. A., & Smith, E. R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.2.311 · Cited by 49
Oncolytic viruses for the treatment of cancer: current strategies and clinical trials
Ries, S. J., & Brandts, C. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03221-0 · Cited by 47
Parkins, C., Stratford, M., Dennis, M. F., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.53 · Cited by 44
Desforges, M., Charron, J., Bérard, S., Beausoleil, S., Stojdl, D. F., Despars, G., Laverdière, B., Bell, J. C., Talbot, P. J., Stanners, C. P., et al. (2001) · Virus Research · doi:10.1016/s0168-1702(01)00251-9 · Cited by 41
Self-citationSolid tumors “melt” from the inside after successful CD8 T cell attack
Blohm, U., Potthoff, D., van der Kogel, A. J., & Pircher, H. (2005) · European Journal of Immunology · doi:10.1002/eji.200526175 · Cited by 38
CXCR2 is critical for dsRNA-induced lung injury: relevance to viral lung infection.
Londhe, V. A., Belperio, J. A., Keane, M. P., Burdick, M. D., Xue, Y., & Strieter, R. M. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-4 · Cited by 35
Au, T., Thorne, S. H., Korn, W. M., Sze, D. Y., Kirn, D. H., & Reid, T. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700988 · Cited by 35
Self-citationMartinive, P., Wever, J. D., Bouzin, C., Baudelet, C., Sonveaux, P., Grégoire, V., Gallez, B., & Féron, O. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0472 · Cited by 34
Schleiffenbaum, B. E., Fehr, J., Odermatt, B. F., & Sperb, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3631 · Cited by 16
Cited by
Tumor-associated neutrophils: friend or foe?
Fridlender, Z. G., & Albelda, S. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs123 · Cited by 699
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Self-citationPark, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Self-citationOncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Oncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Self-citation
Metadata
- Authors
- Breitbach, C. J., Paterson, J. M., Lemay, C. G., Falls, T. J., McGuire, A., Parato, K. A., Stojdl, D. F., Daneshmand, M., Speth, K., Kirn, D., McCart, J. A., Atkins, H., & Bell, J. C.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 15
- Issue
- 9
- Pages
- 1686-1693
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2057672138
- Cited by
- 277
- References
- 36
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.